PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lymphocytic Leukemia

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

August 14, 2019

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

June 17, 2019

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019

June 5, 2019

Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemia

Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemi...

May 16, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us